Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
Category: #health  By Nikita Chaurasia  Date: 2020-01-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycoform of mucin 1) CAR-T (chimeric antigen receptor T-cell) therapy in TnMUC1-positive advanced cancers patients.

This clinical trial is assessing CART-TnMUC1 in patients who are suffering from TnMUC1 positive refractory tumors together with a lymphodepletion chemotherapy regimen. The main aim of this trial is to create safety and the suggested Phase 2 dose of CART-TnMUC1 which can be administered with lymphodepletion.

The clinical trial is presently open to patients who are TnMUC1-positive and have treatment-resistant solid tumors comprising pancreatic ductal adenocarcinoma, metastatic ovarian cancer (involving cancers of the fallopian tube), non-small cell lung cancer, and HR (hormone receptor)-negative and HER2-negative TNBC.

Usman Azam, MD, CEO and President of Tmunity, said that the commencement of the first trial to dose patients with a CART-TnMUC1 is a vital milestone not only for the company but also for the oncology community.

This clinical trial marked the third program from the company’s portfolio to enter the clinical testing phase since its inception in 2015. The company is looking forward to advancing its portfolio of novel cell therapies for unmet demand in solid tumors and strengthening the potential for CAR-T therapeutics, he said.

This therapy was created by a University of Pennsylvania team led by Avery D. Posey, Ph.D., an Asst. Professor of Pharmacology and a member of the University’s Abramson Cancer Center.

Speaking on the trial, Posey said that the key challenge in the field of CAR-T cells is to aim solid tumors and hope to potentially discovery a novel therapeutic approach. With an aim to create more effective cancer therapy, they are testing sweet CARs for targeting a sugar that is expressed in tumor cells, claims Posey.

Source Credit - https://www.biospace.com/article/releases/tmunity-announces-first-patient-dosed-in-phase-1-clinical-trial-with-cart-tnmuc1/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Google sued by Justice Department for illicitly holding monopoly power
Google sued by Justice Department for illicitly holding monopoly power
By Nikita Chaurasia

The U.S. Justice Department has reportedly filed a landmark lawsuit against Google LLC of illegally safeguarding its monopoly in order to dominate the search and advertising vertical. If reports are to be believed, the recent antitrust case against G...

Flybe’s flight services to be revived by Thyme Opco post acquisition
Flybe’s flight services to be revived by Thyme Opco post acquisition
By Nikita Chaurasia

COVID-19 restrictions pushed Flybe into administration in March 2020, putting over 2,400 jobs at risk. The acquisition will allow Flybe to restart its operations as a regional airliner in the U.K. It has been speculated that U.K.-based airline c...

Britain hits an absurdly high average asking price for homes
Britain hits an absurdly high average asking price for homes
By Nikita Chaurasia

Reportedly, the average asking price of houses in Britain has reached an all-time high, with buyers willing to spend more for larger properties after experiencing the COVID-19 lockdown. Sources with relevant information stated that for the first tim...